clinical trial · NCT04647890
Effects of FT011 in Systemic Sclerosis
Scleroderma, SystemicScleroderma, DiffuseSclerosis, SystemicFT011FT011Placebo
brief summary
FT011 is an anti-fibrotic drug that is being tested as a treatment for scleroderma. This study is being conducted to see what the body does to the drug (pharmacokinetics), and what the drug does to the body (pharmacodynamics).
started
Jul 19, 2021
primary completion
Oct 12, 2022
completion
Nov 16, 2022
last updated
Dec 20, 2023
official title
A Phase II, Randomised, Double Blind, Placebo-controlled Study of the Pharmacokinetics, Pharmacodynamic Effects, and Safety, of Oral FT011 in Participants With Diffuse Systemic Sclerosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol